Nurix Therapeutics (NASDAQ: NRIX) furnishes FY 2025 earnings press release

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. filed a current report to note that on January 28, 2026 it issued a press release announcing its financial results for the fiscal quarter and year ended November 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference.

The company clarifies that the information provided under Item 2.02, including Exhibit 99.1, is furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.

00015495952025FYfalse00015495952026-01-282026-01-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 28, 2026

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________

Delaware			001-39398			27-0838048
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)
1600 Sierra Point Parkway Brisbane, California						94005
(Address of Principal Executive Offices)						(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code) 

N/A

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			NRIX			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On January 28, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter and year ended November 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Exhibit Title or Description
99.1						Press Release dated January 28, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NURIX THERAPEUTICS, INC.
Date: January 28, 2026			By:			/s/ Arthur T. Sands
						Arthur T. Sands, M.D., Ph.D.
						President and Chief Executive Officer

3

FAQ

What did Nurix Therapeutics (NRIX) disclose in its January 2026 Form 8-K?

Nurix Therapeutics filed a Form 8-K stating it issued a press release with financial results. The disclosure covers results for the fiscal quarter and year ended November 30, 2025 and furnishes the release as Exhibit 99.1, rather than fully filing it under Exchange Act requirements.

Which financial periods are covered in Nurix Therapeutics (NRIX) latest earnings press release?

The Nurix Therapeutics press release covers financial results for both the fiscal quarter and the full fiscal year ended November 30, 2025. These results are referenced in the Form 8-K and provided as Exhibit 99.1, giving investors a consolidated view of recent operating performance.

Is Nurix Therapeutics (NRIX) January 28, 2026 earnings information considered filed with the SEC?

No, Nurix specifies that the Item 2.02 information, including Exhibit 99.1, is furnished, not filed. This means it is not subject to Section 18 liability of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings by general reference language.

Where can investors find the Nurix Therapeutics (NRIX) earnings press release referenced in the Form 8-K?

Investors can find the earnings press release as Exhibit 99.1 to the Form 8-K. The exhibit contains the detailed financial results for the fiscal quarter and year ended November 30, 2025, as announced by Nurix Therapeutics on January 28, 2026.

On which exchange is Nurix Therapeutics (NRIX) common stock listed and under what symbol?

Nurix Therapeutics common stock is listed on the Nasdaq Global Market under the trading symbol NRIX. The Form 8-K confirms this listing, along with the company’s common stock having a par value of $0.001 per share as its registered class.

Who signed Nurix Therapeutics (NRIX) January 28, 2026 Form 8-K?

The Form 8-K was signed on behalf of Nurix Therapeutics by Arthur T. Sands, M.D., Ph.D., the company’s President and Chief Executive Officer. His signature confirms the company’s authorization of the current report describing the furnished earnings press release.